VRTX Share Price

Open 89.74 Change Price %
High 90.48 1 Day 0.93 1.04
Low 89.12 1 Week -1.94 -2.11
Close 89.98 1 Month 3.91 4.54
Volume 1064364 1 Year 9.40 11.67
52 Week High 103.73
52 Week Low 71.46
VRTX Important Levels
Resistance 2 91.24
Resistance 1 90.72
Pivot 89.86
Support 1 89.24
Support 2 88.72
NASDAQ USA Most Active Stocks
MU 28.43 7.40%
MU 28.43 7.40%
MU 28.43 7.40%
FNFG 10.18 -0.20%
FTR 2.09 7.73%
FTR 2.09 7.73%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
AMCF 0.10 100.00%
VALV 0.04 100.00%
LOCM 0.09 50.00%
BGMD 0.08 33.33%
ESMC 0.12 33.33%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

VRTX Technical Analysis 3
As on 24th Mar 2017 VRTX Share Price closed @ 89.98 and we RECOMMEND Buy for LONG-TERM with Stoploss of 87.48 & Buy for SHORT-TERM with Stoploss of 87.29 we also expect STOCK to react on Following IMPORTANT LEVELS.
VRTX Target for March
1st Target up-side 94.77
2nd Target up-side 97.68
3rd Target up-side 100.59
1st Target down-side 86.47
2nd Target down-side 83.56
3rd Target down-side 80.65
VRTX Other Details
Segment EQ
Market Capital 9959515136.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vrtx.com
VRTX Address
VRTX
50 Northern Avenue
Boston, MA 02210
United States
Phone: 617-341-6100
Interactive Technical Analysis Chart Vertex Pharmaceuticals Incorporated ( VRTX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vertex Pharmaceuticals Incorporated
VRTX Business Profile
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company�s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.